Luca Filippi, MD, PhD, specialist in Pediatrics, Neonatology, Anesthesiology and Resuscitation, is Associate Professor of Pediatrics at Pisa University, Director of the Neonatology Unit, with specific experience in neonatal intensive care. He received Ph.D. in Neonatal Research at Maastricht University (Netherlands). After the observation that propranolol is effective in the regression of infantile hemangiomas, he hypothesized that this drug might be effective also in reducing the progression of ROP and coordinated several clinical trials. Then, he hypothesized that β3-AR upregulation may represent the same strategy adopted by embryo and cancer to growth in a hypoxic environment. He is involved in both studies evaluating the antitumor efficacy of β3-AR antagonist molecules, and in studies evaluating the efficacy of β3-AR agonist drugs to counteract the damage caused by hyperoxia in preterm infants (the so-called pharmacological artificial placenta).